Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primatesAn mRNA vaccine was designed against Orthopoxviruses (including mpox and smallpox) and compared with current standard of care modified vaccinia Ankara (MVA) vaccines in a nonhuman primate model of lethal mpox virus infection. In-depth immunological profiling revealed a critical role for Fab and Fc functions against aspects of poxvirus disease and provided broad pan-Orthopoxvirus immunity.An mRNA vaccine was designed against Orthopoxviruses (including mpox and smallpox) and compared with current standard of care modified vaccinia Ankara (MVA) vaccines in a nonhuman primate model of lethal mpox virus infection. In-depth immunological profiling revealed a critical role for Fab and Fc functions against aspects of poxvirus disease and provided broad pan-Orthopoxvirus immunity.Eric M. Mucker, Alec W. Freyn, Sandra L. Bixler, Deniz Cizmeci, Caroline Atyeo, Patricia L. Earl, Harini Natarajan, Genesis Santos, Tiffany R. Frey, Rafael H. Levin, Anusha Meni, Guha A. Arunkumar, Daniel Stadlbauer, Patricia A. Jorquera, Hamilton Bennett, Joshua C. Johnson, Kath Hardcastle, Jeffrey L. Americo, Catherine A. Cotter, Jeff W. Koehler, Christopher I. Davis, Joshua D. Shamblin, Kristin Ostrowski, Jo Lynne Raymond, Keersten M. Ricks, Andrea Carfi, Wen-Han Yu, Nancy J. Sullivan, Bernard Moss, Galit Alter, Jay W. Hooperhttps://www.cell.com/cell/fulltext/S0092-8674(24)00972-3?rss=yeshttp://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignSeptember 5, 2024

Powered by WPeMatico